Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... Memphis, Tenn. (PRWEB) , ... July 31, 2015 , ... ... at Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to ... partnership focused on cancer research between Methodist Healthcare, The West Clinic and The University ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... Oct. 17 40|86 Strategic Income,Fund (NYSE: CFD ... 9, 2007 to holders of record at the close ... Fund is a closed-end investment management,company. The Fund,s primary ... in the Fund,s prospectus, the Fund intends to,distribute substantially ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... and other medical markets, announced today the appointment,of ... November 1,2007. Mr. Hynes will assume responsibility ... Europe including the UK, Ireland,France and Switzerland. He ...
... (Oct. 17, 2007) -- Two reports from physician-scientists at ... male infertility. A first report shows that a common ... in the scrotum -- also results in a depletion ... that once a common, simple surgery is used to ...
... cancer screening practices, , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... most cervical cancers -- was far better than the standard ... What,s unclear, however, is whether or not the HPV test ... have a slightly higher false positive rate, and it,s not ...
... in men, it could lead to new treatments, study says, ... a gene that,s essential for the formation of functioning sperm ... from being able to penetrate an egg. , The finding, ... Hill, was based on research with mice. But it might ...
... Oct. 17 Good oral health and good ... 15-19) is a great,opportunity to ensure that children ... the nation,s premier, independent oral health advocacy,organization is ... to promote healthy school lunches. Children who learn,good ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell 2Health News:HPV Test Bests Pap Smear in Studies 2Health News:HPV Test Bests Pap Smear in Studies 3Health News:Gene Mutation Key to Infertility in Male Mice 2Health News:Oral Health America Celebrates National School Lunch Week 2
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: